Affinity: Hospital Trial

Overview

Method comparison study to compare the Affinity prototype device using a capillary blood sample against routine venous laboratory results, in patients undergoing systemic anti-cancer therapy (SACT). Tests will be performed by healthcare professionals (Cohort 1) and participants self-testing (Cohort 2)

Full Title of Study: “Affinity: Hospital Trial. Early Prototype Testing for a Home Oncology Monitoring System”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 17, 2022

Detailed Description

In this study the Investigators wish to compare 200 finger prick sample (capillary) blood results taken and analysed using the Affinity prototype device to standard of care venous blood samples, taken from the participant on the same day. The blood tests will analyse Full Blood Count (FBC) 200 patients will be recruited in total. 100 will take part in Cohort 1, where a member of the clinical research team will take their blood sample using the Affinity prototype device. The other 100 will take part in Cohort 2, where the participant will self test and take the blood sample themselves. Participants will be asked to complete a short questionnaire after using the device to provide any feedback on its design and use.

Interventions

  • Diagnostic Test: Capillary finger prick blood sample
    • Patients will have a blood finger prick sample

Arms, Groups and Cohorts

  • Cohort 1
    • Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
  • Cohort 2
    • Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.

Clinical Trial Outcome Measures

Primary Measures

  • To assess the accuracy (bias) of the Affinity prototype device against laboratory testing (capillary vs. venous sample)
    • Time Frame: 1 year
    • Measuring Full Blood Count (FBC)

Secondary Measures

  • Assessment and feedback
    • Time Frame: 1 year
    • To measure the number of issues when the prototype device is used by healthcare professionals (Cohort 1) and participants (Cohort 2).
  • Assessment and feedback
    • Time Frame: 1 year
    • To measure the severity of each issue when the prototype device is used by healthcare professionals (Cohort 1) and participants (Cohort 2).

Participating in This Clinical Trial

Inclusion Criteria

  • Age >18 years old at the time of study entry Currently receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle – Scheduled to be undergoing routine venous laboratory blood tests as part of standard of care – Can provide written informed consent – Cohort 2 only- Able to independently complete participant questionnaires Exclusion Criteria:

  • Receiving systemic anti-cancer therapy for a haematological malignancy – Known parasitic infection – Known inherited or acquired bleeding disorder – History of haematological malignancy – Known poorly controlled anti-coagulation – Cohort 2 only- Participant or carer unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Entia Ltd
  • Collaborator
    • The Christie NHS Foundation Trust
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.